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J Appl Physiol 114: 1222–1234, 2013. First published March 21, 2013;
doi:10.1152/japplphysiol.00981.2012.—Muscle dysfunction often occurs in pa-
tients with chronic obstructive pulmonary disease (COPD) and may involve both
respiratory and locomotor (peripheral) muscles. The loss of strength and/or endur-
ance in the former can lead to ventilatory insufficiency, whereas in the latter it
limits exercise capacity and activities of daily life. Muscle dysfunction is the
consequence of complex interactions between local and systemic factors, frequently
coexisting in COPD patients. Pulmonary hyperinflation along with the increase in
work of breathing that occur in COPD appear as the main contributing factors to
respiratory muscle dysfunction. By contrast, deconditioning seems to play a key
role in peripheral muscle dysfunction. However, additional systemic factors,
including tobacco smoking, systemic inflammation, exercise, exacerbations, nutri-
tional and gas exchange abnormalities, anabolic insufficiency, comorbidities and
drugs, can also influence the function of both respiratory and peripheral muscles, by
inducing modifications in their local microenvironment. Under all these circum-
stances, protein metabolism imbalance, oxidative stress, inflammatory events, as
well as muscle injury may occur, determining the final structure and modulating the
function of different muscle groups. Respiratory muscles show signs of injury as
well as an increase in several elements involved in aerobic metabolism (proportion
of type I fibers, capillary density, and aerobic enzyme activity) whereas limb
muscles exhibit a loss of the same elements, injury, and a reduction in fiber size. In
the present review we examine the current state of the art of the pathophysiology
of muscle dysfunction in COPD.
respiratory muscles; limb muscles; muscle dysfunction; hyperinflation; decondi-
tioning; muscle wasting; exercise; exacerbations
MUSCLE STRUCTURE AND FUNCTION are frequently abnormal in
patients with chronic obstructive pulmonary disease (COPD)
(5, 66, 123). This common systemic manifestation can have
direct clinical consequences among patients since respiratory
muscles are needed for achieving an appropriate level of
alveolar ventilation, whereas lower limb muscles are essential
for daily life activities. In fact, several studies have shown that
muscle dysfunction reduces both the health-related quality of
life and the life expectancy of COPD patients (118, 158, 191).
The present review is to a great extent an introduction to eight
other minireviews of the highlighted topic on COPD muscle
dysfunction. In those reviews, the most relevant biological
contributors to muscle dysfunction in COPD will be exten-
sively discussed. Therefore, in the following sections we will
1) discuss its definition, principal physiological concepts, and
factors involved in its pathogenesis; and 2) review from a
general perspective the main clinical, cellular, and molecular
mechanisms that contribute to dysfunction in both respiratory
and locomotor muscles.
MUSCLE DYSFUNCTION: DEFINITION AND MAIN
PHYSIOLOGICAL CONCEPTS
Muscle dysfunction is defined as the loss of at least one of
the two main muscle properties: strength and endurance (64).
The former corresponds to the capacity to develop a short
maximal contractile effort, whereas the latter is characterized
by the ability to maintain a submaximal exercise load through-
out a more prolonged period of time. Strength mainly depends
on muscle mass (which in turn is determined by the size and
density of the fibers), muscle resting length, velocity of short-
ening, and the recruitment pattern of motor units (87). Con-
versely, endurance is mainly determined by the coordination of
all different elements involved in oxygen delivery and utiliza-
tion by the muscle (type I fiber proportion, capillary density,
and oxidative enzyme activities, among others) (5). Muscle
strength can be easily assessed by means of its direct determi-
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nation using dynamometry (limb muscles) or the measurement
of maximal respiratory pressures (respiratory muscles) both in
clinical and experimental settings (5, 179, 208). In general
maximal efforts are obtained through voluntary maneuvers but
the use of either electrical or magnetic stimulation avoids
relying on the subject’s full collaboration (117, 120). Muscle
endurance is more difficult to assess but can be evaluated using
tests that involve the use of either progressive loads or a
continuous submaximal load until exhaustion. It is worth
noting that in this latter modality the outcome variable is time,
which is most appropriate to reflect endurance. In any case,
both strategies are useful to explore this functional property
either in peripheral or respiratory muscles (28, 156, 157).
The concept of muscle dysfunction includes the presence of
at least one of the following conditions: weakness, reduced
endurance, and fatigue. Either muscle weakness, characterized
by a reduction in muscle force, or reduced muscle endurance
are relatively stable situations, which can be easily identified
(see above). The restoration of either muscle force or endur-
ance requires medium- or long-term therapeutic measures,
including strength training and nutritional interventions, and
endurance training, respectively (5). Conversely, muscle fa-
tigue implies a temporary loss of the contractile function that
can be reversed by rest. Muscle fatigue can be partial or
complete, involving in this case the total inability to further
maintain the effort. Moreover, muscle fatigue might also be
considered as acute or chronic depending on whether its
development occurs suddenly or gradually over time (53).
However, the concept of chronic fatigue is controversial and
has lost support in recent years. Fatigue can also be divided
into central and peripheral, depending on whether its origin lies
on the nervous system or muscle structures, respectively (53).
Muscle fatigue can be identified through neurophysiological or
mechanical indicators, both revealing the transient inability to
perform a target task. These indicators revert to a physiological
level under resting conditions. Importantly, weakness, reduced
endurance, and fatigue can be present simultaneously in the
same patient. Moreover, a weak muscle will become fatigued
much more easily. Muscle dysfunction in COPD is the end
result of a complex interaction between several factors, which,
in turn, induce many different molecular and cellular events
within the muscle (10, 11, 14, 38, 137, 171). These factors and
their biological consequences are not always equivalent for
respiratory and limb muscles. For this reason, in the following
sections these two muscle groups will be reviewed separately.
RESPIRATORY MUSCLES
Inspiratory muscles expand the thoracic cage generating the
negative alveolar pressure that results in inspiratory flow.
Among them, the diaphragm has been classically considered as
the main inspiratory muscle, at least in healthy and young
subjects breathing under resting conditions. However, when
the ventilatory demands increase as a result of aging, respira-
tory diseases, and/or exercise, other muscles progressively
participate in the breathing effort, becoming even more rele-
vant than the diaphragm (24, 42, 44). In these cases, the
external and parasternal (the interchondral extension of the
internal interosseus) intercostals become major players. The
diaphragm is a dome-shaped muscle, which is composed by
costal and crural parts, acting mainly by expanding the lower
rib cage (41). Whereas the costal part appears to be more
relevant for inspiration, the crural portion also plays a relevant
role in the gastroesophageal function (187). Contraction of
external and parasternal intercostal muscles enlarges mostly
the global chest cross-sectional area, whereas scalenes expand
the upper rib cage. The diaphragm, parasternal intercostals, and
scalenes are considered as primary inspiratory muscles, since
they are phasically recruited with each inspiration. Muscles
that are inactive under normal ventilatory conditions, and are
recruited only upon increased ventilatory demands, are called
accessory muscles. The combined action of inspiratory mus-
cles expanding the thorax and the elastic recoil of the lung
results in a more negative pleural pressure, which is transmit-
ted to the alveolar region and causes the entry of air into the
lungs.
Although expiration is normally a passive process, second-
ary to the relaxation of the inspiratory muscles, air exhalation
can be facilitated by the contraction of other muscle groups,
including those of the abdominal wall and the internal inter-
costals. This action along with the air trapping that may
concomitantly occur appears to be involved in the increase of
dyspnea and lack of bronchodilator response shown by some
COPD patients (111, 139).
The function of respiratory muscles, which is frequently
impaired in COPD patients (165, 203), may contribute to
hypercapnic respiratory failure and exercise limitation. Respi-
ratory muscle dysfunction has been associated with an in-
creased risk for repeated hospital admissions (203) and prema-
ture death (158). As already mentioned, respiratory muscle
dysfunction in COPD is caused by the combination of different
local and systemic factors (Fig. 1). On the one hand, muscles
are facing an increase in mechanical ventilatory loads. Since
COPD is mainly characterized by airflow limitation, as well as
pulmonary hyperinflation and increased compliance, this will
have important mechanical consequences. Different elastic
(derived from changes in the thorax wall and lung paren-
chyma), resistive (caused by air passage through the narrowed
airways) and threshold (such as that derived from the intrinsic
positive end-expiratory pressure, PEEPI) loads increase in
patients (53, 65, 66), thus imposing an increased work of
breathing and overloading respiratory muscles (53, 166). On
the other hand, static pulmonary hyperinflation modifies thorax
geometry, shortening the diaphragmatic length (166, 182), a
situation that can be even accentuated by dynamic pulmonary
hyperinflation. In this regard, the diaphragm is displaced away
from its optimal length to generate force, and its costal and
crural parts probably become less coordinated (110). All these
factors lead to a mismatching between mechanical require-
ments of the respiratory system and functional capacity of the
ventilatory muscles, as well as between the metabolic demands
and the energy supply to these muscles (66, 204).
Besides local influences, a number of systemic factors may
also negatively affect this already adverse scenario in the
respiratory muscles. These systemic factors, which can also be
present in other muscle groups, include systemic inflammation,
pulmonary gas exchange and nutritional abnormalities, the
systemic consequences of concomitant disorders, and the direct
effects of tobacco and some drugs used in the treatment of
COPD patients, such as systemic steroids (13, 39, 43, 180) (see
next sections). All in all, this leads to more metabolic derange-
ments superimposed on top of the mechanical factors discussed
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above. Further, these factors (and perhaps some others that still
remain unidentified) induce a series of cellular and molecular
events within the muscles that can have a negative effect on
their structure and function. Muscle damage (137), the pres-
ence of local oxidative stress (11, 119) and inflammatory
elements (24), the activation of proteolytic pathways (193), and
even some signs of a true myopathy (for instance the presence
of paracrystalline inclusions) (109), have been described in
respiratory muscles of COPD patients and can jeopardize their
function (Table 1).
Certainly, the diaphragm of hyperinflated COPD patients
develops less force than that of healthy subjects when both
groups are making the effort at their own functional residual
capacity (FRC). However, the situation becomes completely
different if healthy volunteers are forced to increase their lung
volume to similar levels than those of the patients. Then, it has
been shown that the latter group can develop even greater
diaphragmatic force than the former (182). This suggests that
to some extent respiratory muscles undergo a beneficial adap-
tation in COPD that coexists with the negative scenario that has
been described in previous paragraphs. It is believed that this
adaptation also derives from the increase in mechanical loads
that occurs in the respiratory system of COPD patients, which
would emulate muscle training. The molecular and cellular
changes that are believed to be induced by this “training effect”
in the diaphragm of COPD patients include shorter sarcomeres
(136), increases in the proportion of myosin heavy chain I
(MyHC-I), type I fibers (45, 103), capillary contacts per fiber
(45), and mitochondrial density (136), and enhanced mitochon-
drial respiratory chain capacity (163, 207).
Whereas changes in sarcomere length would partially coun-
terbalance the negative effects induced by the displacement of
the diaphragm length-tension curve on diaphragmatic force in
COPD patients, the other changes would confer the muscle an
enhanced aerobic capacity. Importantly, some of these modi-
fications are not restricted to the diaphragm since they have
also been found in other respiratory muscles (85, 104, 163).
This is the case of the external intercostal muscle of COPD
patients, which has shown an increased oxidative capacity
in vitro (163), probably related to its higher capillary density
and enhanced activity of different enzymes involved in the
aerobic pathways (85, 163, 172). However, no significant
changes have been consistently found in the proportion of type
I fibers in this muscle. By contrast, in the only study published
so far in which the structure of the parasternal muscles was
analyzed in COPD patients, an increase in the percentage of
type I fibers and MyHC-I was reported (104).
In summary, in patients with COPD many different factors
can influence respiratory muscle structure and function, acting
in opposite directions. A few of them exert clear deleterious
effects, while others may also exert a beneficial influence that
would counterbalance, at least in part, the impact of the former.
Therefore, it can be assumed that respiratory muscles operate
in a sort of delicate balance in COPD. Any additional delete-
rious event taking place in this precarious scenario (i.e., exac-
erbation, exercise) may easily lead to ventilatory failure.
LOCOMOTOR MUSCLES
Functional impairment of limb muscles (often referred to as
peripheral muscles) is present in about one-third of COPD
patients, having important clinical consequences for them,
since it is associated with low exercise tolerance (72), a
reduction in quality of life (132), greater use of health care
resources (40) and higher mortality (191). Numerous studies
have demonstrated the loss of muscle strength that occurs in
the limbs of patients with COPD (16, 72, 73, 79, 156). Most of
these studies have been performed in lower limb muscles,
especially the quadriceps (16, 73, 79), although there are also
some studies in upper limb muscles (72, 156). Interestingly, the
decline in limb muscle strength, and particularly that of the
quadriceps muscle, has been shown to be two to four times
faster in COPD patients than in healthy individuals (79).
Although limb muscle endurance has been less studied than
strength, different studies have shown that this functional
property is also reduced in COPD patients (28, 196, 199). It
should be noted that limb muscle dysfunction may occur even
in individuals exhibiting mild to moderate airway obstruction
(179). Moreover, limb muscle dysfunction is absent in half of
the COPD patients with severe disease (179). This interindi-
vidual heterogeneity for the same level of lung function im-
pairment implies that the latter is not the main factor that
causes muscle dysfunction in COPD patients. There are many
evidences that suggest that a significant role should be attrib-
Leading Factor Other Factors
Changes in
Ventilatory 
Mechanics
Muscle
Deconditioning
RESPIRATORY 
MUSCLES
PERIPHERAL
MUSCLES
Genetics
Nutritional status
Anabolism/Catabolism
Gas exchange
Systemic Inflammation
Tobacco
Exacerbations
Exercise
Co-morbidities / Aging
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Fig. 1. Main factors thought to contribute to respiratory
and/or peripheral muscle dysfunction in chronic obstructive
pulmonary disease (COPD). Pulmonary hyperinflation ap-
pears as the main factor contributing to respiratory muscle
dysfunction, whereas deconditioning seems to play the key
role in limb muscle dysfunction. However, additional sys-
temic factors, such as tobacco smoking, systemic inflamma-
tion, intense exercise, exacerbations, nutritional and gas
exchange abnormalities, anabolic insufficiency, comorbidi-
ties, and drugs also modulate muscle function.
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uted to muscle deconditioning (or “detraining”), which would
result primarily from the sedentary lifestyle that frequently
follows the increased breathlessness during exercise that char-
acterizes COPD (Fig. 1) (20, 66). Interestingly, limb muscle
dysfunction can also contribute to a further reduction in phys-
ical activity, generating a vicious circle. Moreover, it has been
shown that maintenance of even a moderate level of physical
activity reduces hospital admissions (59), and is associated
with better functional status (61) and life expectancy (59) in
COPD patients, while it delays lung functional decline and
even COPD risk in smokers (60). Three main arguments
support the key pathogenic role attributed to muscle decondi-
tioning in limb muscle dysfunction. First is the fact that
functional and structural impairment appears to be more pro-
nounced in lower limb than in upper limb muscles (63, 64, 76),
which are believed to be less severely exposed to the conse-
quences of a reduction in physical activity (63). Second, many
of the changes and phenomena reported in peripheral muscles
of COPD patients (this will be reviewed in more detail in other
reviews of the present highlighted topic) are quite similar to
those described in muscle disuse (17, 26, 27). This is the case,
for instance, of fiber atrophy, decreased percentage of aerobic
fibers, reductions in the activity of oxidative enzymes and
capillary density, as well as the presence of oxidative stress and
early lactate release during exercise (66, 144). Third, most of
these findings can be partially reversed by muscle training
(114, 135). However, some other abnormalities such as marked
cachexia or increased muscle oxygen consumption at isocharge
(171) still persist despite training, suggesting the presence of
additional factors that are also involved in the pathogenesis of
peripheral muscle dysfunction in COPD. Those factors are
most probably of systemic nature and presumably include
genetic background, tobacco smoking, aging and comorbidi-
ties, systemic inflammation, exacerbations, intense exercise,
nutritional and gas exchange abnormalities, anabolic/catabolic
hormone imbalance, and the effects of some drugs (5, 66).
SYSTEMIC FACTORS INVOLVED IN MUSCLE DYSFUNCTION
A controversial issue refers to which elements related to
muscle dysfunction in COPD would be considered ethiopatho-
genic factors, and which others should be treated as mecha-
nisms of such a dysfunction or merely as muscle findings. In
this regard, in the present review, “factors” have been defined
as those elements of systemic origin that may influence muscle
function in COPD patients. However, events occurring inside
the muscle tissue, which in turn, may provoke further structural
or biological derangements or even directly alter muscle func-
tion, have been defined as “mechanisms.” Since many of the
systemic factors involved in the impairment of muscle function
will be extensively discussed in the other minireviews of this
Highlighted Topic, in the present review, the different mech-
anisms potentially involved in COPD muscle dysfunction will
be discussed using a rather general approach.
Systemic inflammation. The inflammatory response may lead
to the activation of different cellular pathways that can result in
muscle atrophy and/or muscle dysfunction. This is the case of
apoptosis, autophagy, oxidative stress, and catabolic systems
such as that of the ubiquitin proteasome (62). Furthermore,
certain proinflammatory cytokines can directly inhibit muscle
contraction (161). Systemic inflammation may occur in pa-Ta
bl
e
1.
M
ai
n
st
ru
ct
ur
al
a
n
d
fun
cti
on
al
fin
din
gs
de
sc
rib
ed
in
sk
el
et
al
m
u
sc
le
s
o
fC
O
PD
pa
tie
nt
s
Fi
be
rs
Ca
pi
lla
rit
y
M
ito
ch
on
dr
ia
M
us
cl
e
In
jur
y
O
xi
da
tiv
e
St
re
ss
Lo
ca
l
In
fla
m
m
at
io
n
A
po
pt
os
is
Pr
ot
ei
n
Im
ba
la
nc
e
O
xi
da
tiv
e
Ca
pa
ci
ty
Co
nt
ra
ct
ili
ty
D
ef
ec
t
Re
sp
ir
at
or
y
M
us
cl
es
D
ia
ph
ra
gm
Ty
pe
-I
%
1
D
en
sit
y
1
D
en
sit
y
1
Ce
lls

,
1
(T
UN
EL
)
Pr
es
en
t
1
Pr
es
en
t
Si
ze
2
/
Co
nt
ac
ts
1
In
cl
us
io
ns
pr
es
en
t
1
1
Cy
to
ki
ne
s
1

(E
M
)
O
/G
1
/
A
bn
or
m
al
fu
nc
tio
n*
Ex
te
rn
al
in
te
rc
os
ta
ls
Ty
pe
-I
%
2
/
D
en
sit
y
1
D
en
sit
y
1
1
N
A
Ce
lls


(T
UN
EL
)
N
A
1
A
bs
en
t
Si
ze

A
bn
or
m
al
fu
nc
tio
n
Cy
to
ki
ne
s
1

(E
M
)
O
/G
2
/
Pa
ra
st
er
na
ls
Ty
pe
-I
%
1
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
Si
ze

Ex
te
rn
al
o
bl
iq
ue
Ty
pe
-I
%
2
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
Si
ze

Pe
ri
ph
er
al
M
us
cl
es
Qu
ad
ric
ep
sm
u
sc
le
Ty
pe
-I
%
2
Co
nt
ac
ts
2
D
en
sit
y
2
1
1
Ce
lls
1
1
(T
UN
EL
)
Pr
es
en
t
2
N
ot
cl
ea
r
Si
ze
2
/
A
bn
or
m
al
fu
nc
tio
n*
Cy
to
ki
ne
s
2
/1

(E
M
)
O
/G
2
Ti
bi
al
is
an
te
rio
r
N
A
D
en
sit
y
2
D
en
sit
y
2
Po
ss
ib
le
N
A
N
A
N
A
N
A

N
A
Co
nt
ac
ts
2
D
el
to
id
m
u
sc
le
Ty
pe
I
%

N
A
N
A
N
A
N
A
N
A
N
A
N
A
O
/G

N
A
Si
ze
1

2
B
ic
ep
s
br
ac
hi
i
Ty
pe
I
%
1
/
N
A
N
A
N
A
N
A
N
A
N
A
N
A
O
/G

N
A
Si
ze
2
O
th
er
M
us
cl
es
La
tis
sim
us
do
rs
i
Ty
pe
I
%

N
A
A
bn
or
m
al
fu
nc
tio
n
N
A
N
A
N
A
N
A
N
A
O
/G

N
A
Si
ze
1
CO
PD
,c
hr
on
ic
o
bs
tru
ct
iv
ep
ul
m
on
ar
y
di
se
as
e;
TU
N
EL
,t
er
m
in
al
de
ox
yn
uc
le
ot
id
yl
tr
an
sf
er
as
e
dU
TP
n
ic
k
en
d
la
be
lin
g;
EM
,e
le
ct
ro
n
m
ic
ro
sc
op
y
(ul
tra
st
ru
ct
ur
al
an
al
ys
is)
;O
/G
,o
x
id
at
iv
e/
gl
yc
ol
yt
ic
en
zy
m
e
ra
tio
;c
o
n
tr
ac
til
ity
de
fe
ct
:f
or
ce
ge
ne
ra
tio
n
in
iso
la
te
d
fib
er
s.
N
A
,n
o
da
ta
av
ai
la
bl
e;

,
u
n
ch
an
ge
d;
/,
o
r;

,
co
ex
ist
en
ce
;*
,
re
sp
ira
to
ry
ch
ai
n
ca
pa
ci
ty
2
an
d
re
ac
tiv
e
o
x
yg
en
sp
ec
ie
s
1
.
Review
1225Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
tients with COPD as shown in different reports, in which
increases in blood levels of white cells and different biomark-
ers such as C-reactive protein, fibrinogen, and several proin-
flammatory cytokines have been demonstrated (43, 58). Ini-
tially, it was thought that systemic inflammation found in
COPD derives from that which occurs primarily in the lung,
which would spread later on to the rest of the body through the
bloodstream (“spillover” theory) (183). However, the absence
of correlations between the level of inflammatory markers in
the lung and blood or other organs including muscles, and the
presence of muscle changes preceding pulmonary abnormali-
ties strongly argue against this possibility (13, 66, 183). This
suggests that extrapulmonary manifestations of COPD may
start in parallel to the lung disease, being the direct conse-
quence of the same insults. Another intriguing question is to
elucidate the mechanisms involved in the perpetuation of the
inflammatory response after cessation of the initial stimulus.
Recent evidence seems to indicate that these mechanisms are
probably related to an abnormal immunologic response (19). It
should be noted, however, that not all authors have been able
to find systemic inflammation in stable COPD patients (43, 90,
192). In fact, this situation is much more evident during
exacerbations (90).
Systemic oxidative stress. Reactive oxygen species (ROS)
are a product of the aerobic metabolism and are normally
present in different tissues including muscles. However, when
there is an imbalance between the production of ROS and the
antioxidant systems, oxidative stress occurs leading to delete-
rious changes in different key molecules and tissue damage
(66). Oxidative stress and inflammation are mutually interre-
lated. Whereas the former can act as a signal for the expression
of inflammatory mediators (65), the latter (along with other
factors such as a reduced blood flow, hypoxia and contractile
activity) can modulate the level of ROS production and there-
fore of oxidative stress (65, 190) (Fig. 2). Oxidative stress has
been found not only in the lungs but also in the blood and
muscles of stable COPD patients (10, 11, 155, 167). Moreover,
both exacerbations and exercise can increase plasma and/or
muscle levels of oxidative stress markers (12, 77, 90).
Although the relationships between systemic oxidative
stress and muscle dysfunction are not yet clearly elucidated,
a direct relationship has been found between the level of
oxidative stress within the muscle tissue and muscle func-
tion impairment (11).
Gas exchange abnormalities. Both hypoxia and hypercapnia
may have deleterious effects on muscle function in COPD
patients (2, 94). Muscle hypoxia can be present in such patients
due to the reduction in oxygen delivery to the tissues (141)
derived from their hypoxemia and the frequent coexistence of
anemia (212). Hypoxia may induce systemic inflammation,
oxidative stress, protein imbalance, apoptosis and impaired
muscle regeneration (22, 67, 99, 214), generating a reduction in
muscle mass and targeting different elements involved in the
oxidative capacity of muscles (80, 141). Therefore, it is not
surprising that hypoxia can lead to impaired muscle strength
and endurance in COPD patients (66). Hypercapnia, in turn,
may act in skeletal muscles directly or through inducing a
decrease in extracellular and cellular pH. Whereas hypercapnia
has been shown to induce muscle dysfunction both in normal
subjects and in COPD patients (2, 154), acidosis may induce
impaired muscle proteostasis (balance between protein synthe-
sis and breakdown) (52).
Inefficiency of anabolic hormones. Growth hormone is an
anabolic agent that induces an increase in the production of the
insulin-like growth factor 1 (IGF-1), subsequently promoting
an increment in protein synthesis and inhibition of protein
degradation (54). Therefore, it results in muscle growth and
increases in muscle mass (106). The levels of the growth
hormone can be reduced, normal, or even increased in COPD
patients (112, 176), but its interaction with IGF-I seems to be
altered (33), potentially leading to reductions in muscle mass.
Although exogenous growth hormone increases body weight
and muscle mass in undernourished COPD patients, no clear
effects have been demonstrated in muscle function (23).
Testosterone is a steroid hormone secreted by the gonads
and to a lesser extent by the adrenals that has relevant anabolic
effects. Its levels are much higher in men than in women,
participating in the differential development of their muscle
mass. Testosterone increases the synthesis of muscle structural
proteins, an action that can lead to muscle hypertrophy (21).
Different authors have shown that testosterone levels can be
low in COPD patients, potentially leading to a reduced muscle
mass (91, 100). However, the implications of this hypogonad-
ism on muscle dysfunction are not clear, since either muscle
strength and endurance or exercise capacity appears to remain
unaltered (100). The mechanisms of testosterone deficiency in
COPD remain unclear although aging, hypoxia, smoking, and
steroid therapy might be involved (5, 33).
Comorbidities and aging. With the increase in life expec-
tancy in developed societies, the number of elderly COPD
patients is becoming very high. One of the main causes of
muscle functional impairment in aged populations is sarcope-
nia, characterized by the loss of skeletal muscle mass and
changes in muscle characteristics (fiber atrophy and loss,
Stimuli
- Proinflammatory mediators
- By-products of the Arachidonic acid
- ROS  & NO production, Oxidative/Nitrosative stress
Muscle
Dysfunction
Modifications in structural proteins
Modifications in enzymes
Lipid peroxidation
DNA damage
Tobacco
Exercise
Exacerbations
Abnormal gas exchange
Nutritional abnormalities
Fig. 2. Role and relationships of inflamma-
tion and oxidative stress in skeletal muscle
dysfunction of COPD patients. Factors in-
volved. ROS, reactive oxygen species.
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fibrosis, degeneration of the neuromuscular junction) (129),
both leading to muscle dysfunction (66). Moreover, changes in
muscle mass and muscle dysfunction are also frequent in
highly prevalent comorbidities of COPD such as chronic car-
diac failure, diabetes, and cancer (35, 160, 188).
Tobacco. Despite the difficulties to separate the effects of
tobacco smoking from those of COPD, it is known that nons-
ymptomatic smokers often complain of whole body fatigability
(29), showing less muscle resistance (131). Moreover, evi-
dence emerging from animal and human studies supports the
fact that tobacco smoking may induce muscle dysfunction
through different mechanisms (13, 210). These include oxida-
tive stress, inflammation, imbalance between protein synthesis
and degradation within the muscle, neuromuscular transmis-
sion failure, tampering in the oxidative capacity of the muscle
and CO toxicity (13, 140, 210, 215).
Exercise and training. The understanding of muscle adap-
tations to exercise and training is essential for the analysis of
the factors leading to muscle dysfunction in COPD. Exercise is
necessary to maintain an appropriate performance in skeletal
muscles. However, intense exercise can induce metabolic
changes (lipolysis, dysregulation of carbohydrate use, altered
amino acid kinetics) (56, 57), systemic inflammation, systemic
and local (muscle) oxidative stress (30, 31), hampered expres-
sion of key muscle genes regulated by the nuclear transcription
factor kappa B (NF-B) (such as those encoding inflammatory
cytokines, antioxidants, heat-shock proteins, and antiapoptotic
factors) (126), muscle damage (137), and muscle function
impairment (98) in COPD patients. Interestingly, some of these
findings are more evident in those individuals with low body
weight (56, 57, 198).
Compared with healthy subjects, some COPD patients ex-
hibit an abnormally high muscle oxygen uptake and ATP
consumption at a given submaximal mechanical load during
exercise (101, 102, 164, 171). While the mechanism underly-
ing this phenomenon, known as mechanical-energetic ineffi-
ciency, is unclear in COPD, in chronic cardiac failure nitroso-
redox imbalance seems to be a main contributing factor (12,
74, 75, 167, 184). Interestingly, recent studies using systems
biology approaches have analyzed differences between COPD
patients and healthy sedentary subjects regarding skeletal mus-
cle transcriptomes (195) and proteomes (12) together with
altered blood metabolomes (168). These studies have shown
that patients exhibit a lack of correlation between the expres-
sion of genes involved in bioenergetics and tissue remodeling
pathways, as well as an abnormal expression of enzymes
involved in chromatin modification (195). Moreover, some of
these abnormalities as well as an abnormal amino acidic profile
observed in blood (168) seem to be more evident in patients
exhibiting muscle wasting. These findings may suggest the
presence of altered myogenesis and the activation of epigenetic
mechanisms in skeletal muscles of COPD patients. Besides, the
failure to activate relevant skeletal muscle pathways in a
coordinated fashion would eventually lead to the development
of structural changes. Finally, the significant association found
between a number of histone modifiers and peak oxygen
uptake during exercise in COPD patients supports the hypoth-
esis that cell hypoxia also plays a role in muscle dysfunction
(195). Taken together, it is possible to speculate that in periph-
eral muscles of COPD patients an abnormal interplay between
sedentarism and the systemic factors would result in altered
muscle structure and biology (including impaired regeneration
and remodeling capacity) leading to the occurrence of muscle
dysfunction.
It is widely accepted that standard training programs are
clinically beneficial at any stage of the disease (171). However,
the effects of training on muscles of COPD patients are much
more complex. In contrast with healthy subjects, who show a
marked enhancement in their muscle antioxidant potential after
training, COPD patients exhibit only a minor increase or even
a decrease (152, 153). Again, this phenomenon is especially
important in those patients with muscle wasting (153), in
whom high-intensity endurance training may induce oxidative
stress at muscle level over the first weeks (12). Interestingly,
these effects seem to be transient, not being evident at the end
of training programs of standard duration (8 wk) (167). It is of
note that training-induced adaptations of COPD patients, re-
flected in muscle transcriptomic and blood metabolomic pro-
files (168, 195), show abnormalities consistent with the alter-
ations alluded to above, such as abnormal amino acid metab-
olism and altered tissue remodeling. Additionally, training
does not modify the abnormal relationships observed between
cell bioenergetics and tissue remodeling (195).
Exacerbations. COPD patients exhibiting respiratory or pe-
ripheral muscle weakness have an increased risk of hospital
admissions due to exacerbations of their disease (6, 203).
Moreover, exacerbations appear to further contribute to muscle
wasting and dysfunction (142, 185, 203), probably as a result
of the increased systemic inflammation and oxidative stress (1,
34, 185), infection, marked physical inactivity (142), and
negative energy imbalance (32, 82, 200) that characterize these
episodes, as well as some of the drugs used in their treatment
(39). Moreover, multiple pathways involved in muscle dys-
function (ubiquitin-dependent protein catabolism, apoptosis,
oxidative stress, among others) seem to concomitantly occur
under these circumstances (34). Therefore, it is not surprising
that muscle functional impairment develops quickly during
exacerbations, lasting for a relatively long time (185). Inactiv-
ity again appears to play a leading role in the loss of muscle
mass and function taking place during the course of exacerba-
tions, as training was shown to prevent, at least in part, this
impairment (170) through upregulating anabolic pathways in
muscles (194).
Muscle wasting. Patients with COPD often show nutritional
abnormalities, while a subgroup is clearly cachectic (9, 178,
201, 209). Moreover, malnourishment often associates with
muscle weakness (5, 201) and poor prognosis (202, 211),
which is believed to be the result of the interaction between
different factors, including reduced energy intake, systemic
inflammation, enhanced lipolysis and, of particular interest, a
mismatching between muscle protein synthesis and degrada-
tion (50, 51, 78, 96, 130, 146, 177, 213). Skeletal muscles are
major protein stores, and some of the amino acids that compose
these proteins are potential sources of energy. Therefore, it is
not surprising that, under conditions involving an increase in
energy expenditure (8, 177), muscle proteolysis becomes in-
creased. In COPD, this occurs mostly through activation of the
ubiquitin-proteasome system (34, 46, 55, 143). The proteasome
is a cellular structure that degrades proteins (mostly those
previously tagged with ubiquitins through different ligases)
and peptides (especially those which have been modified by
oxidative stress) (18, 133, 162, 173, 186, 197) (Fig. 3). In
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contrast, other biological pathways such as mitogen-activated
protein kinases (MAPK), myogenin, myostatin, and oxidants
(which will act as second messengers), do not seem to play a
major role in the activation of proteolysis in these patients. A
key point to better understand the relationships between muscle
wasting and muscle dysfunction in COPD is to clearly identify
the differences present in the quadriceps muscle of patients
with normal and low body weight. In this regard, the latter
show 1) more abnormal transcriptomic and proteomic profiles
(12, 195); 2) more reduced protein synthesis (48, 130); 3) in-
creased levels of protein ubiquitination (55); 4) higher levels of
nitrosative stress and activation of NF-B (4, 55); 5) a lower
exercise-induced increase (or even a decrease) in antioxidants
(152, 153); and 6) a significant loss of structural proteins and
content of key enzymes (55, 128), as well as smaller fibers
(55), when compared with patients with normal body weight.
Drugs. Different drugs used in COPD patients for the
treatment of the disease or its comorbidities can induce
changes in skeletal muscles. Corticosteroids, especially when
used systemically, can induce both acute and chronic myopa-
thies. Although the systemic use of these drugs has decreased
considerably, they are still useful in exacerbations and in those
patients with a very advanced disease. The acute form of the
steroid-induced myopathy is characterized by rhabdomyolysis
and the loss of thick myosin filaments both resulting in marked
weakness that may affect different muscle groups (159, 205).
This myopathy can be observed mostly following the admin-
istration of high doses of corticosteroids (89). The chronic
myopathy induced by these drugs, in turn, is usually the result
of a long-term administration of even moderate doses (39),
being characterized by the atrophy of type II fibers, abnormal-
ities in carbohydrate metabolism and a negative balance in
protein metabolism (39, 107). All these changes result in
muscle weakness, characterized in this case by targeting prox-
imal muscle groups (39).
Anticholinergic drugs are widely used in patients with
COPD because of its relaxing effect of the bronchial smooth
muscle, which favors bronchodilation. They do not have rele-
vant effects on skeletal muscles at standard doses, but at higher
levels can lead to a reduction in the contractile reaction time
and to muscle dysfunction (92, 151). Other drugs used fre-
quently in patients with COPD are inhibitors of phosphodies-
terase 4 and 5 (PDE4 and PDE5, respectively), which act by
relaxing smooth muscles. Whereas PDE4 is used to reduce
airway inflammation and bronchoconstriction, PDE5 is being
employed to treat primary and secondary pulmonary hyperten-
sion (25, 97). An interesting effect of PDE5 is its potential in
reducing muscle damage in some myopathies (7). However,
some of the phosphodiesterase inhibitors have also been shown
to reduce the effects of insulin on skeletal muscles and might
result in an impairment in their function (113). Finally, there is
a wide variety of drugs used in cardiovascular comorbidities of
COPD that may also have harmful effects on skeletal muscles.
This is the case of -blockers that can facilitate muscle
fatigue (88), calcium channel blockers that can reduce
contraction and attenuate muscle regeneration (145), statins
that can induce a specific myopathy (97), and some diuretics
that can induce dyselectrolytemia, potentially tampering
muscle function (124).
SKELETAL MUSCLE FINDINGS AND LOCAL MECHANISMS
A significant number of studies have investigated the met-
abolic and structural changes that occur in skeletal muscles.
Most of these studies were conducted in limb muscles, given
the difficulties to have access to samples of respiratory mus-
cles. Since the findings reported in the latter have already been
mentioned in a previous section this part will focus on periph-
eral muscles. The changes that have been described in this
muscle group vary (Table 1) but can be classified according
with their potential effects. In this regard, different authors
have shown 1) reduced muscle mass (122, 169) and fiber size
(55, 68, 206), likely to be related, at least in part, to the
concomitant imbalance between protein synthesis (reduced)
and breakdown (enhanced) (36, 37, 38); 2) reductions in the
expression of the MyHC-I isoform, percentage of type-I fibers,
mitochondrial density, capillary density and capillary-fiber
ratio, myoglobin content, and activities of different key oxida-
tive enzymes (69, 70, 83, 84, 86, 115, 174, 181, 206); 3) mi-
tochondrial abnormalities including an increase in the local
production of ROS (147, 148, 149, 150), uncoupling in oxida-
tive pathways (83, 115, 134, 175), abnormal transition pore
kinetics and cytochrome c release, and changes in mitochon-
drial DNA (12, 134, 147); and 4) oxidative stress (targeting
Proteasome
PA700 (19S)
Ubiquitin protein conjugate
Non ubiquitinated short peptide
Resulting 
Short amino acid chains
20S Proteasome
Heptameric
rings
Active sites for
Proteolysis 
(β subunits)
Anchorage site
(α subunits)
20S Proteasome
26S Proteasome
Complex
PA28 (11S)
PA700 (19S)
polyubiquitin chain
Fig. 3. Proteolytic pathways: 26S (left) and
20S-PA28(11S) (right) proteasome com-
plexes. The 26S proteasome is composed of
two regulator structures (PA700) and a cata-
lytic core (20S proteasome), which in turn
consists of two inner and two outer heptam-
eric rings forming a cylinder. Proteolysis
occurs in the inner rings ( subunits) whereas
each one of the outer rings ( subunits) acts
as an anchor point for a PA700 (19S). Ubi-
quitinated proteins enter to this structure and
become degradated. The 20S unit can also be
attached to other structure, named PA28 (11S),
which is able to degradated short peptides that
have been previously modified by reactive ox-
ygen species and are nonubiquitinated.
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DNA and essential structural proteins and enzymes) (10, 11,
55, 150), local inflammation (14, 125, 127), enhanced apopto-
sis (3, 14), sarcolemmal and sarcomera damage (138), and a
reduction in the expression of key-molecules involved in mus-
cle growth and regeneration (i.e., myogenin and m-cadherin)
(55; Martínez-Llorens JM, unpublished observations). Signif-
icantly, although some authors have suggested the involvement
of autophagy in muscle dysfunction (81), its presence has not
been demonstrated to date (143). Some of the abnormalities
mentioned here such as those included in point 1 will have a
main impact on muscle strength (66), whereas others such as
those referred to mostly in point 2 would impair the aerobic
components of the muscle predominantly targeting muscle
endurance (196), or may contribute to impaired muscle bioen-
ergetics such as those included in point 3 (49, 171), or would
tamper directly the contractile properties of the muscle result-
ing in muscle dysfunction in general as for those mentioned in
point 4. It should be noted that some of the changes found in the
quadriceps and tibialis anterior muscles such as the decrease in the
proportion of type I fibers are more pronounced in patients with
more severe COPD (71), while others can be seen even in
mild-to-moderate stages of the disease (10). It is also impor-
tant to highlight that most of the studies mentioned here
were performed using quadriceps muscle samples (most
often obtained from its vastus lateralis portion). Therefore,
some findings may not be directly extrapolated to other
peripheral muscles, and especially to those located in the
upper limbs. This is the case, for instance, for the reported
reduced activity of oxidative enzymes or fiber atrophy
described in the quadriceps and/or the tibialis anterior that
appear to be absent or less marked in the deltoid muscle
(63, 76).
Taken together, the abovementioned hallmarks would char-
acterize an impaired limb muscle phenotype that becomes
inadequate to correctly perform its functional tasks, thus con-
tributing to the patients’ exercise limitation. In fact, this limb
muscle phenotype can be considered as less balanced than that
of respiratory muscles, where negative and positive changes
coexist in COPD patients.
FUTURE PERSPECTIVES
Current evidence emerging from a great deal of investiga-
tions conducted in the last two decades has clearly demon-
strated the contribution of different local and systemic factors
and several molecular and cellular mechanisms to muscle
dysfunction in COPD. However, although these biological
insights have certainly enhanced our knowledge on this clinical
problem, a complete and comprehensive view of its etiology is
still lacking. The incorporation of new technical and concep-
tual advances in basic sciences as well as new perspectives
such as those coming from the bioinformatics and bioengineer-
ing fields might help investigators working on this specific
arena to address questions from complementary points of view.
In this regard, epigenetic studies and recent multilevel analyses
using systems biology-medicine approaches are already gen-
erating novel and fascinating hypotheses (15, 105, 189, 195),
which will eventually provide new biological insights account-
ing for the skeletal muscle dysfunction of COPD patients, in
hopes that a more comprehensive understanding of the problem
will be achieved in the near future. This should lead to new
therapeutic and even prophylactic approaches for the manage-
ment of COPD muscle dysfunction.
CONCLUSIONS
Muscle dysfunction is a common manifestation among
COPD patients. Both local and systemic factors play a relevant
role in its pathogenesis. Among the former, mechanical imbal-
ance due to increased preloads and hyperinflation constitute the
main factor that contributes to respiratory muscle dysfunction,
whereas deconditioning due to reduced physical activity is the
main driver of peripheral muscle dysfunction. As to the effects
of the systemic contributors, tobacco, nutritional and gas ex-
change abnormalities, exercise, exacerbations, systemic in-
flammation, and drugs are believed to also contribute to muscle
dysfunction in patients with COPD. All these factors are able
to modify the local microenvironment of the muscle, resulting
in protein imbalance, injury, local inflammation, and oxidative
stress, among other phenomena, subsequently determining
muscle structure and function.
GRANTS
This work was supported by Grants SAF2007-62719, SAF2011-26908,
Marató TV3 2007, and 2005SGR01060.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: J.G. analyzed data; J.G. prepared figures; J.G., A.A.,
and J.R. drafted manuscript; J.G., A.A., and J.R. edited and revised manu-
script; J.G., A.A., and J.R. approved final version of manuscript.
REFERENCES
1. Abdellaoui A, Préfaut C, Gouzi F, Couillard A, Coisy-Quivy M,
Hugon G, Molinari N, Lafontaine T, Jonquet O, Laoudj-Chenivesse
D, Hayot M. Skeletal muscle effects of electrostimulation after COPD
exacerbation: a pilot study. Eur Respir J 38: 781–788, 2011.
2. Aguar MC, Gea J, Aran X, Guiu R, Orozco-Levi M, Broquetas JM.
Modifications in the mechanical activity of the diaphragm induced by the
inhalation of CO2 in patients with chronic obstructive pulmonary disease.
Arch Bronconeumol 29: 226–228, 1993.
3. Agustí AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle
S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 166: 485–
489, 2002.
4. Agustí A, Morlá M, Sauleda J, Saus C, Busquets X. NF-kappaB
activation and iNOS upregulation in skeletal muscle of patients with
COPD and low body weight. Thorax 59: 483–487, 2004.
5. American Thoracic Society. Skeletal muscle dysfunction in chronic
obstructive pulmonary disease: a statement of the American Thoracic
Society and European Respiratory Society. Am J Respir Crit Care Med
159: S1–S40, 1999.
6. Ansari K, Keaney N, Taylor I, Burns G, Farrow M. Muscle weakness,
health status and frequency of exacerbations in chronic obstructive
pulmonary disease. Postgrad Med J 88: 372–376, 2012.
7. Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE.
Primary role of functional ischemia, quantitative evidence for the two-hit
mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscu-
lar dystrophy. PLoS One 2: e806, 2007.
8. Baarends EM, Schols AM, Pannemans DL, Westerterp KR, Wouters
EF. Total free living energy expenditure in patients with severe chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 155: 549–
554, 1997.
9. Balcells E, Antó JM, Gea J, Gómez FP, Rodríguez E, Marin A,
Ferrer A, de Batlle J, Farrero E, Benet M, Orozco-Levi M, Ferrer J,
Agustí AG, Gáldiz JB, Belda J, Garcia-Aymerich J; Study Group
Review
1229Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
PACCOPD. Characteristics of patients admitted for the first time for
COPD exacerbation. Respir Med 103: 1293–1302, 2009.
10. Barreiro E, Gea J, Corominas JM, Hussain SN. Nitric oxide synthases
and protein oxidation in the quadriceps femoris of patients with chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol 29: 771–778,
2003.
11. Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S,
Hussain S, Gea J. Oxidative stress and respiratory muscle dysfunction in
severe COPD. Am J Respir Crit Care Med 171: 1116–1124, 2005.
12. Barreiro E, Rabinovich R, Marin-Corral J, Barbera` JA, Gea J, Roca
J. Chronic endurance exercise induces quadriceps nitrosative stress in
patients with severe COPD. Thorax 64: 13–19, 2009.
13. Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J,
Sánchez F, Gea J, Barbera` JA; in COPD Project ENIGMA. Cigarette
smoke-induced oxidative stress: A role in chronic obstructive pulmonary
disease skeletal muscle dysfunction. Am J Respir Crit Care Med 182:
477–488, 2010.
14. Barreiro E, Ferrer D, Sanchez F, Minguella J, Marin-Corral J,
Martinez-Llorens J, Lloreta J, Gea J. Inflammatory cells and apoptosis
in respiratory and limb muscles of patients with COPD. J Appl Physiol
111: 808–817, 2011.
15. Barreiro E, Sznajder JI. Epigenetic regulation of muscle phenotype
and adaptation: a potential role in COPD muscle dysfunction. J Appl
Physiol. (Published ahead of print January 10, 2013). doi:10.1152/
japplphysiol.01027.2012.
16. Bernard S, Leblanc P, Whittom F, Carrier G, Jobin J, Belleau R,
Maltais F. Peripheral muscle weakness in patients with chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med 158: 629–634, 1998.
17. Bloomfield SA. Changes in musculoskeletal structure and function with
prolonged bed rest. Med Sci Sports Exerc 29: 197–206, 1997.
18. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA,
Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ,
Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ.
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Science 294: 1704–1708, 2001.
19. Borchers MT, Wesselkamper SC, Curull V, Ramirez-Sarmiento A,
Sánchez-Font A, Garcia-Aymerich J, Coronell C, Lloreta J, Agusti
AG, Gea J, Howington JA, Reed MF, Starnes SL, Harris NL, Vitucci
M, Eppert BL, Motz GT, Fogel K, McGraw DW, Tichelaar JW,
Orozco-Levi M. Sustained CTL activation by murine pulmonary epi-
thelial cells promotes the development of COPD-like disease. J Clin
Invest 119: 636–649, 2009.
20. Bossenbroek L, de Greef MH, Wempe JB, Krijnen WP, Ten Hacken
NH. Daily physical activity in patients with chronic obstructive pulmo-
nary disease: a systematic review. COPD 8: 306–319, 2011.
21. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement
on muscle mass and muscle protein synthesis in hypogonadal men—a
clinical research center study. J Clin Endocrinol Metab 81: 3469–3475,
1996.
22. Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an
update. Apoptosis 7: 475–482, 2002.
23. Burdet L, de Muralt B, Schutz Y, Pichard C, Fitting JW. Adminis-
tration of growth hormone to underweight patients with chronic obstruc-
tive pulmonary disease. A prospective, randomized, controlled study. Am
J Respir Crit Care Med 156: 1800–1806, 1997.
24. Casadevall C, Coronell C, Ramírez-Sarmiento AL, Martínez-Llorens J,
Barreiro E, Orozco-Levi M, Gea J. Upregulation of pro-inflammatory
cytokines in the intercostal muscles of COPD patients. Eur Respir J 30:
701–707, 2007.
25. Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors
for chronic obstructive pulmonary disease. Cochrane Database Syst Rev
5: CD002309, 2011.
26. Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling
pathways involved in skeletal muscle disuse-induced atrophy and the
impact of countermeasures. J Cell Mol Med 13: 3032–3050, 2009.
27. Convertino VA, Bloomfield SA, Greenleaf JE. An overview of the
issues: physiological effects of bed rest and restricted physical activity.
Med Sci Sports Exerc 29: 187–190, 1997.
28. Coronell C, Orozco-Levi M, Méndez R, Ramírez-Sarmiento A,
Gáldiz JB, Gea J. Relevance of assessing quadriceps endurance in
patients with COPD. Eur Respir J 24: 129–136, 2004.
29. Corwin EJ, Klein LC, Rickelman K. Predictors of fatigue in healthy
young adults: moderating effects of cigarette smoking and gender. Biol
Res Nurs 3: 222–233, 2002.
30. Couillard A, Koechlin C, Cristol JP, Varray A, Prefaut C. Evidence
of local exercise-induced systemic oxidative stress in chronic obstructive
pulmonary disease patients. Eur Respir J 20: 1123–1129, 2002.
31. Couillard A, Maltais F, Saey D, Debigaré R, Michaud A, Koechlin C,
LeBlanc P, Préfaut C. Exercise-induced quadriceps oxidative stress and
peripheral muscle dysfunction in patients with chronic obstructive pul-
monary disease. Am J Respir Crit Care Med 167: 1664–1669, 2003.
32. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener
MA, Schols AM. Disturbances in leptin metabolism are related to energy
imbalance during acute exacerbations of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 162: 1239–1245, 2000.
33. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic
obstructive pulmonary disease. Eur Respir J Suppl 46: 76s–80s, 2003.
34. Crul T, Testelmans D, Spruit MA, Troosters T, Gosselink R,
Geeraerts I, Decramer M, Gayan-Ramirez G. Gene expression pro-
filing in vastus lateralis muscle during an acute exacerbation of COPD.
Cell Physiol Biochem 25: 491–500, 2010.
35. Davis MP. The emerging role of palliative medicine in the treatment of
lung cancer patients. Cleve Clin J Med 79, Electronic Suppl 1: eS51–
eS55, 2012.
36. Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic
obstructive pulmonary disease. Clinical relevance and mechanisms. Am J
Respir Crit Care Med 164: 1712–1717, 2001.
37. Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A,
LeBlanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in
patients with COPD. Chest 124: 83–89, 2003.
38. Debigaré R, Côté CH, Maltais F. Ubiquitination and proteolysis in limb
and respiratory muscles of patients with chronic obstructive pulmonary
disease. Proc Am Thorac Soc 7: 84–90, 2010.
39. Decramer M, de Bock V, Dom R. Functional and histologic picture of
steroid-induced myopathy in chronic obstructive pulmonary disease. Am
J Respir Crit Care Med 153: 1958–1964, 1996.
40. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G.
Muscle weakness is related to utilization of health care resources in
COPD patients. Eur Respir J 10: 417–423, 1997.
41. De Troyer A, Sampson M, Sigrist S, Macklem PT. The diaphragm:
two muscles. Science 213: 237–238, 1981.
42. De Troyer A. The electro-mechanical response of canine inspiratory
intercostal muscles to increased resistance: the caudal rib-cage. J Physiol
451: 463–476, 1992.
43. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis
factor-alpha levels and weight loss in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 150: 1453–1455, 1994.
44. DiMarco AF, Romaniuk JR, Supinski GS. Parasternal and external
intercostal responses to various respiratory maneuvers. J Appl Physiol
73: 979–986, 1992.
45. Doucet M, Debigare R, Joanisse DR, Cote C, Leblanc P, Gregoire J,
Deslauriers J, Vaillancourt R, Maltais F. Adaptation of the diaphragm
and the vastus lateralis in mild-to-moderate COPD. Eur Respir J 24:
971–979, 2004.
46. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron
MA, LeBlanc P, Maltais F. Muscle atrophy and hypertrophy signaling
in patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 176: 261–269, 2007.
47. Eisner MD, Iribarren C, Blanc PD, Yelin EH, Ackerson L, Byl N,
Omachi TA, Sidney S, Katz PP. Development of disability in chronic
obstructive pulmonary disease: beyond lung function. Thorax 66: 108–
114, 2011.
48. Engelen MP, Deutz NE, Wouters EF, Schols AM. Enhanced levels of
whole-body protein turnover in patients with chronic obstructive pulmo-
nary disease. Am J Respir Crit Care Med 162: 1488–1492, 2000.
49. Engelen MP, Schols AM, Does JD, Gosker HR, Deutz NE, Wouters
EF. Exercise-induced lactate increase in relation to muscle substrates in
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 162: 1697–1704, 2000.
50. Engelen MP, Wouters EF, Deutz NE, Menheere PP, Schols AM.
Factors contributing to alterations in skeletal muscle and plasma amino
acid profiles in patients with chronic obstructive pulmonary disease. Am
J Clin Nutr 72: 1480–1487, 2000.
51. Engelen MP, Wouters EF, Deutz NE, Does JD, Schols AM. Effects of
exercise in amino acid metabolism in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 163: 859–864, 2001.
Review
1230 Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
52. England BK, Chastain JL, Mitch WE. Abnormalities in protein syn-
thesis and degradation induced by extracellular pH in BC3H1 myocytes.
Am J Physiol Cell Physiol 260: C277–C282, 1991.
53. Epstein SK. An overview of respiratory muscle function. Clin Chest
Med 15: 619–639, 1994.
54. Estívariz CF, Ziegler TR. Nutrition and the insulin-like growth factor
system. Endocrine 7: 65–71, 1997.
55. Fermoselle C, Rabinovich R, Ausín P, Puig-Vilanova E, Coronell C,
Sanchez F, Roca J, Gea J, Barreiro E. Does oxidative stress modulate
limb muscle atrophy in severe COPD patients? Eur Respir J 40: 851–
862, 2012.
56. Franssen FM, Sauerwein HP, Rutten EP, Wouters EF, Schols AM.
Whole-body resting and exercise-induced lipolysis in sarcopenic [cor-
rected] patients with COPD. Eur Respir J 32: 1466–1471, 2008.
57. Franssen FM, Sauerwein HP, Ackermans MT, Rutten EP, Wouters
EF, Schols AM. Increased postabsorptive and exercise-induced whole-
body glucose production in patients with chronic obstructive pulmonary
disease. Metabolism 60: 957–964, 2011.
58. Gan WQ, Man WQ, Senthilselvan A, Sin DD. Association between
chronic obstructive pulmonary disease and systemic inflammation: a
systematic review and a meta-analysis. Thorax 59: 574–580, 2004.
59. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular
physical activity reduces hospital admission and mortality in chronic
obstructive pulmonary disease: a population based cohort study. Thorax
61: 772–778, 2006.
60. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular
physical activity modifies smoking-related lung function decline and
reduces risk of chronic obstructive pulmonary disease: a population-
based cohort study. Am J Respir Crit Care Med 175: 458–63, 2007.
61. Garcia-Aymerich J, Serra I, Gómez FP, Farrero E, Balcells E,
Rodríguez DA, de Batlle J, Gimeno E, Donaire-Gonzalez D, Orozco-
Levi M, Sauleda J, Gea J, Rodriguez-Roisin R, Roca J, Agustí AG,
Antó JM; and Course of COPD Study Group. Phenotype, physical
activity, and clinical and functional status in COPD. Chest 136: 62–70,
2009.
62. Gass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways.
Int Biochem Cell Biol 37: 1974–1984, 2005.
63. Gea J, Pasto M, Carmona MA, Orozco-Levi M, Palomeque J,
Broquetas J. Metabolic characteristics of the deltoid muscle in patients
with chronic obstructive pulmonary disease. Eur Respir J 17: 939–945,
2001.
64. Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural
and functional changes in the skeletal muscles of COPD patients: the
“compartments” theory. Monaldi Arch Chest Dis 56: 214–224, 2001.
65. Gea J, Barreiro E, Orozco-Levi M. Free radicals, cytokines and
respiratory muscles in COPD patients. Clin Pulm Med 14: 117–126,
2007.
66. Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E. Respi-
ratory diseases and muscle dysfunction. Expert Rev Respir Med 6: 75–90,
2012.
67. Gonzalez NC, Wood JG. Alveolar hypoxia-induced systemic inflam-
mation: what low PO2 does and does not do. Adv Exp Med Biol 662:
27–32, 2010.
68. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der
Vusse GJ, Wouters EF, Schols AM. Muscle fiber type IIX atrophy is
involved in the loss of fat-free mass in chronic obstructive pulmonary
disease. Am J Clin Nutr 76: 113–119, 2002.
69. Gosker HR, van Mameren H, van Dijk PJ, Engelen MP, van der
Vusse GJ, Wouters EF, Schols AM. Skeletal muscle fibre-type shifting
and metabolic profile in patients with chronic obstructive pulmonary
disease. Eur Respir J 19: 617–625, 2002.
70. Gosker HR, Hesselink MK, Duimel H, Ward KA, Schols AM.
Reduced mitochondrial density in the vastus lateralis muscle of patients
with COPD. Eur Respir J 30: 73–79, 2007.
71. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type
shifting in the vastus lateralis of patients with COPD is associated with
disease severity: a systematic review and meta-analysis. Thorax 62:
944–949, 2007.
72. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness
contributes to exercise limitation in COPD. Am J Respir Crit Care Med
153: 976–980, 1996.
73. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength,
symptom intensity, and exercise capacity in patients with cardiorespira-
tory disorders. Am J Respir Crit Care Med 152: 2021–2031, 1995.
74. Hare JM. Nitric oxide and excitation-contraction coupling. J Mol Cell
Cardiol 35: 719–729, 2003.
75. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J
Med 351: 2112–2114, 2004.
76. Hernández N, Orozco-Levi M, Belalcázar V, Pastó M, Minguella J,
Broquetas JM, Gea J. Dual morphometrical changes of the deltoid
muscle in patients with COPD. Respir Physiol Neurobiol 134: 219–229,
2003.
77. Heunks LM, Viña J, van Herwaarden CL, Folgering HT, Gimeno A,
Dekhuijzen PN. Xanthine oxidase is involved in exercise-induced oxi-
dative stress in chronic obstructive pulmonary disease. Am J Physiol
Regul Integr Comp Physiol 277: R1697–R1704, 1999.
78. Hofford JM, Milakofsky L, Vogel WH, Sacher RS, Savage GJ, Pell
S. The nutritional status in advanced emphysema associated with chronic
bronchitis. A study of amino acid and catecholamine levels. Am Rev
Respir Dis 141: 902–908, 1990.
79. Hopkinson NS, Tennant RC, Dayer MJ, Swallow EB, Hansel TT,
Moxham J, Polkey MI. A prospective study of decline in fat free mass
and skeletal muscle strength in chronic obstructive pulmonary disease.
Respir Res 8: 25, 2007.
80. Hoppeler H, Desplanches D. Muscle structural modifications in hyp-
oxia. Int J Sports Med 13, Suppl 1: S166–S168, 1992.
81. Hussain SN, Sandri M. Role of autophagy in COPD skeletal muscle
dysfunction. J Appl Physiol (Published ahead of print October 18, 2012).
doi:10.1152/japplphysiol.00893.2012.
82. Jagoe RT, Engelen MP. Muscle wasting and changes in muscle protein
metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl
46: 52s–63s, 2003.
83. Jakobsson P, Jordfelt L, Henriksson. Metabolic enzyme activity in the
quadriceps femoris muscle in patients with severe chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 151: 374–377, 1995.
84. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and
fiber types in patients with advanced chronic obstructive pulmonary
disease (COPD), with and without chronic respiratory failure. Eur Respir
J 3: 192–196, 1996.
85. Jimenez M, Gea J, Aguar MC, Minguella J, Lloreta J, Félez M,
Broquetas J. Capillary density and respiratory function in the external
intercostal muscle. Arch Bronconeumol 35: 471–476, 1999.
86. Jobin J, Maltais F, Doyon JF, LeBlanc P, Simard PM, Simard AA,
Simard C. Chronic obstructive pulmonary disease: capillarity and fiber-
type characteristics of skeletal muscle. J Cardiopulm Rehabil Prev 18:
432–437, 1998.
87. Jones DA. Skeletal muscle physiology: structure, biomechanics, and
biochemistry. In: The Thorax Part A: Physiology, edited by Roussos Ch.
New York: Dekker, 1995, p 3–32.
88. Kaiser P, Hylander B, Eliasson K, Kaijer L. Effect of beta1-selective
and nonselective beta blockade on blood pressure relative to physical
performance in men with systemic hypertension. Am J Cardiol 55:
79D–84D, 1985.
89. Kaminski HJ, Ruff RL. Endocrine myopathies (hyper- and hypofunc-
tion of adrenal, thyroid, pituitary, and parathyroid glands), and iatrogenic
corticosteroid myopathy. In: Myology, edited by Engel AG, Franzini-
Armstrong C. New York: McGraw-Hill, 1994, p. 1726–1733.
90. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. Biomarkers of
systemic inflammation in stable and exacerbation phases of COPD. Lung
186: 403–409, 2008.
91. Karadag F, Ozcan H, Karul AB, Yilmaz M, Cildag O. Sex hormone
alterations and systemic inflammation in chronic obstructive pulmonary
disease. Int J Clin Pract 63: 275–281, 2009.
92. Karatas GK, Günedi Z. Do anticholinergics affect reaction time? A
possible impact on the course of rehabilitation. Neurorehabilitation 27:
141–145, 2010.
93. Keim NL, Luby MH, Braun SR, Martin AM, Dixon RM. Dietary
evaluation of outpatients with chronic obstructive pulmonary disease. J
Am Diet Assoc 86: 902–906, 1986.
94. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with
COPD: cause, effects, and disease progression. Int J Chron Obstruct
Pulmon Dis 6: 199–208, 2011.
95. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell
EJM. Exercise capacity and ventilatory, circulatory, and symptom lim-
itation in patients with chronic airflow obstruction. Am Rev Respir Dis
146: 935–940, 1992.
96. King DA, Cordova F, Scharf SM. Nutritional aspects of chronic
obstructive pulmonary disease. Proc Am Thorac Soc 5: 519–523, 2008.
Review
1231Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
97. Koda-Kimble MA, Young LY, Alldredge BK, Corelli RL, Guglielmo
BJ, Kradjan WA, Williemas BR. Applied Therapeutics (IX ed.).
Philadelphia, PA: Lippincott Williams & Wilkins, 2009.
98. Koechlin C, Couillard A, Simar D, Cristol JP, Bellet H, Hayot M,
Prefaut C. Does oxidative stress alter quadriceps endurance in chronic
obstructive pulmonary disease? Am J Respir Crit Care Med 169: 1022–
1027, 2004.
99. Kulisz A, Chen N, Chandel NS, Shao Z, Schumacker PT. Mitochon-
drial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in
cardiomyocytes. Am J Physiol Lung Cell Mol Physiol 282: L1324–
L1329, 2002.
100. Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bammert C,
Tobin MJ. Respiratory and skeletal muscles in hypogonadal men with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:
598–605, 2005.
101. Layec G, Haseler LJ, Hoff J, Richardson RS. Evidence that a higher
ATP cost of muscular contraction contributes to the lower mechanical
efficiency associated with COPD: preliminary findings. Am J Physiol
Regul Integr Comp Physiol 300: R1142–R1147, 2011.
102. Layec G, Haseler LJ, Richardson RS. The effect of higher ATP cost of
contraction on the metabolic response to graded exercise in patients with
chronic obstructive pulmonary disease. J Appl Physiol 112: 1041–1048,
2012.
103. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in
the diaphragm in chronic obstructive pulmonary disease. N Engl J Med
337: 1799–1806, 1997.
104. Levine S, Nguyen T, Friscia M, Zhu J, Szeto W, Tikunov BA,
Rubinstein NA, Kaiser LR, Shrager JB. Parasternal intercostal muscle
remodeling in severe chronic obstructive pulmonary disease. J Appl
Physiol 101: 1297–1302, 2006.
105. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD,
Moxham J, Hopkinson NS, Polkey MI, Kemp PR. Downregulation of
the serum response factor/miR-1 axis in the quadriceps of patients with
COPD. Thorax 67: 26–34, 2012.
106. Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B,
Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR.
Systematic review: the effects of growth hormone on athletic perfor-
mance. Ann Intern Med 148: 747–758, 2008.
107. Lieu F, Powers SK, Herb RA, Criswell D, Martin D, Wood C,
Stainsby W, Chen CL. Exercise and glucocorticoid-induced diaphrag-
matic myopathy. J Appl Physiol 75: 763–771, 1993.
108. Liu Q, Xu WG, Luo Y, Han FF, Yao XH, Yang TY, Zhang Y, Pi WF,
Guo XJ. Cigarette smoke-induced skeletal muscle atrophy is associated
with up-regulation of USP-19 via p38 and ERK MAPKs. J Cell Biochem
112: 2307–2316, 2011.
109. Lloreta J, Orozco-Levi M, Gea J, Broquetas J. Selective diaphrag-
matic mitochondrial abnormalities in a patient with marked airflow
obstruction. Ultrastruct Pathol 20: 67–71, 1996.
110. Macklem PT, Gross D, Grassino GA, Roussos C. Partitioning of
inspiratory pressure swings between diaphragm and intercostal/accessory
muscles. J Appl Physiol 44: 200–208, 1978.
111. Macklem PT. Exercise in COPD: damned if you do and damned if you
don’t. Thorax 60: 887–888, 2005.
112. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic ob-
structive pulmonary disease. Respir Res 2: 216–224, 2001.
113. Mahajan H, Richards SM, Rattigan S, Clark MG. T-1032, a cyclic
GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-
mediated muscle hemodynamic effects and glucose uptake in vivo. Br J
Pharmacol 140: 1283–1291, 2003.
114. Maltais F, Leblanc P, Simard C, Jobin J, Berubé C, Bruneau J,
Carrier L, Belleau R. Skeletal muscle adaptation to endurance training
in patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 154: 442–447, 1996.
115. Maltais F, LeBlanc P, Whittom F, Simard C, Marquis K, Bélanger
M, Breton MJ, Jobin J. Oxidative enzyme activities of the vastus
lateralis muscle and the functional status in patients with COPD. Thorax
55: 848–853, 2000.
117. Man WD, Moxham J, Polkey MI. Magnetic stimulation for the mea-
surement of respiratory and skeletal muscle function. Eur Respir J 24:
846–860, 2004.
118. Mangueira NM, Viega IL, Mangueira Mde A, Pinheiro AN, Costa
Mdo R. Correlation between clinical parameters and health-related
quality of life in women with COPD. J Bras Pneumol 35: 248–255,
2009.
119. Marin-Corral J, Minguella J, Ramírez-Sarmiento AL, Hussain SN,
Gea J, Barreiro E. Oxidised proteins and superoxide anion production
in the diaphragm of severe COPD patients. Eur Respir J 33 : 1309–1319,
2009.
120. Martínez-Llorens J, Coronell C, Ramírez-Sarmiento A, Orozco-Levi
M, Espadaler JM, Bautista Gáldiz J, Gea J. Determination of maximal
diaphragm strength in chronic obstructive pulmonary disease: cervical
magnetic stimulation versus traditional sniff maneuver. Arch Bronconeu-
mol 42: 509–515, 2006.
122. Mathur S, Takai KP, Macintyre DL, Reid D. Estimation of thigh
muscle mass with magnetic resonance imaging in older adults and people
with chronic obstructive pulmonary disease. Phys Ther 88: 219–30,
2008.
123. McKenzie DK, Butler JE, Gandevia SC. Respiratory muscle function
and activation in chronic obstructive pulmonary disease. J Appl Physiol
107: 621–629, 2009.
124. McParland C, Resch EF, Krishnan B, Wang Y, Cujec B, Gallagher
CG. Inspiratory muscle weakness in chronic heart failure: role of nutri-
tion and electrolyte status and systemic myopathy. Am J Respir Crit Care
Med 151: 1101–1107, 1995.
125. Menon MK, Houchen L, Singh SJ, Morgan MD, Bradding P, Steiner
MC. Inflammatory and satellite cells in the quadriceps of patients with
COPD and the response to resistance training. Chest 142: 1134–1142,
2012.
126. Mercken EM, Hageman GJ, Langen RC, Wouters EF, Schols AM.
Decreased exercise-induced expression of nuclear factor-B-regulated
genes in muscle of patients with COPD. Chest 139: 337–346, 2011.
127. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernández N,
Tálamo C. Skeletal muscle inflammation and nitric oxide in patients
with COPD. Eur Respir J 26: 390–397, 2005.
128. Morla M, Iglesias A, Sauleda J, Cosio B, Agustí A, Busquets X.
Reduced expression of the sarcoplasmic calcium pump SERCA2 in
skeletal muscle from patients with chronic obstructive pulmonary disease
and low body weight. Arch Bronconeumol 43: 4–8, 2007.
129. Morley JE. Sarcopenia in the elderly. Fam Pract 29, Suppl 1: i44–i48,
2012.
130. Morrison WL, Gibson JN, Scrimgeour C, Rennie MJ. Muscle wasting
in emphysema. Clin Sci (Lond) 75: 415–420, 1988.
131. Morse CI, Wüst RC, Jones DA, de Haan A, Degens H. Muscle fatigue
resistance during stimulated contractions is reduced in young male
smokers. Acta Physiol (Oxf) 191: 123–129, 2007.
132. Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM.
Tissue depletion and health related quality of life in patients with chronic
obstructive pulmonary disease. Respir Med 94: 859–867, 2000.
133. Nader GA. Molecular determinants of skeletal muscle mass: getting the
“AKT” together. Int J Biochem Cell Biol 37: 1985–1996, 2005.
134. Naimi AI, Bourbeau J, Perrault H, Baril J, Wright-Paradis C, Rossi
A, Taivassalo T, Sheel AW, Rabøl R, Dela F, Boushel R. Altered
mitochondrial regulation in quadriceps muscles of patients with COPD.
Clin Physiol Funct Imaging 31: 124–131, 2011.
135. O’Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise
improves muscle strength and may improve elements of performance of
daily activities for people with COPD: a systematic review. Chest 136:
1269–1283, 2009.
136. Orozco-Levi M, Gea J, Lloreta J, Félez M, Minguella J, Serrano S,
Broquetas JM. Subcellular adaptation of the human diaphragm in
chronic obstructive pulmonary disease. Eur Respir J 13: 371–378, 1999.
137. Orozco-Levi M, Lloreta J, Minguella J, Serrano S, Broquetas J, Gea
J. Injury of the human diaphragm associated with exertion and COPD.
Am J Respir Crit Care Med 164: 1734–1739, 2001.
138. Orozco-Levi M, Coronell C, Ramírez-Sarmiento A, Lloreta J, Mar-
tínez-Llorens JM, Gáldiz JB, Gea J. Injury of peripheral muscles in
smokers with chronic obstructive pulmonary disease. Ultrastruct Pathol
36: 228–238, 2012.
139. Pepin V, Saey D, Laviolette L, Maltais F. Exercise capacity in chronic
obstructive pulmonary disease: mechanisms of limitation. COPD 4:
195–204, 2007.
140. Petersen AM, Magkos F, Atherton P, Selby A, Smith K, Rennie MJ,
Pedersen BK, Mittendorfer B. Smoking impairs muscle protein syn-
thesis and increases the expression of myostatin and MAFbx in muscle.
Am J Physiol Endocrinol Metab 293: E843–E848, 2007.
141. Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E,
Patakas D. Tumor necrosis factor-alpha serum levels, weight loss and
Review
1232 Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
tissue oxygenation in chronic obstructive pulmonary disease. Respir Med
96: 594–598, 2002.
142. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink
R. Physical activity and hospitalization for exacerbation of COPD. Chest
129: 536–544, 2006.
143. Plant PJ, Brooks D, Faughnan M, Bayley T, Bain J, Singer L, Correa
J, Pearce D, Binnie M, Batt J. Cellular markers of muscle atrophy in
chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 42:
461–471, 2010.
144. Polkey MI, Moxham J. Attacking the disease spiral in chronic obstruc-
tive pulmonary disease. Clin Med 6: 190–196, 2006.
145. Porter GA, Makuck RF, Rivkees SA. Reduction in intracellular cal-
cium levels inhibits myoblast differentiation. J Biol Chem 277: 28942–
28947, 2002.
146. Pouw EM, Schols AM, Deutz NE, Wouters EF. Plasma and muscle
amino acid levels in relation to resting energy expenditure and inflam-
mation in stable chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 158: 797–801, 1998.
147. Puente-Maestu L, Pérez-Parra J, Godoy R, Moreno N, Tejedor A,
Torres A, Lázaro A, Ferreira A, Agustí A. Abnormal transition pore
kinetics and cytochrome C release in muscle mitochondria of patients
with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol
40: 746–750, 2009.
148. Puente-Maestu L, Pérez-Parra J, Godoy R, Moreno N, Tejedor A,
González-Aragoneses F, Bravo JL, Alvarez FV, Camaño S, Agustí A.
Abnormal mitochondrial function in locomotor and respiratory muscles
of COPD patients. Eur Respir J 33: 1045–1052, 2009.
149. Puente-Maestu L, Lázaro A, Tejedor A, Camaño S, Fuentes M,
Cuervo M, Navarro BO, Agustí A. Effects of exercise on mitochondrial
DNA content in skeletal muscle of patients with COPD. Thorax 66:
121–127, 2011.
150. Puente-Maestu L, Tejedor A, Lázaro A, de Miguel J, Alvarez-Sala L,
González-Aragoneses F, Simón C, Agustí A. Site of mitochondrial
ROS production in skeletal muscle of COPD and its relationship with
exercise oxidative stress. Am J Respir Cell Mol Biol 47: 358–362, 2012.
151. Qiu Z, Zhao D, Shi Y, Liu Y. The effects of high dose atropine on
function of isolated diaphragmatic preparation of rats with omethoate
poisoning. Zhonghua Nei Ke Za Zhi 40: 187–189, 2001.
152. Rabinovich RA, Ardite E, Troosters T, Carbó N, Alonso J, Gonzalez
de Suso JM, Vilaró J, Barbera` JA, Polo MF, Argilés JM, Fernandez-
Checa JC, Roca J. Reduced muscle redox capacity after endurance
training in patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 164: 1114–1118, 2001.
153. Rabinovich RA, Ardite E, Mayer AM, Polo MF, Vilaró J, Argilés
JM, Roca J. Training depletes muscle glutathione in patients with
chronic obstructive pulmonary disease and low body mass index. Res-
piration 73: 757–761, 2006.
154. Rafferty GF, Lou Harris M, Polkey MI, Greenough A, Moxham J.
Effect of hypercapnia on maximal voluntary ventilation and diaphragm
fatigue in normal humans. Am J Respir Crit Care Med 160: 1567–1571,
1999.
155. Rahman I. Oxidative stress and gene transcription in asthma and chronic
obstructive pulmonary disease: antioxidant therapeutic targets. Curr
Drug Targets Inflamm Allergy 1: 291–315, 2002.
156. Ramírez-Sarmiento A, Orozco-Levi M, Barreiro E, Méndez R, Fer-
rer A, Broquetas J, Gea J. Expiratory muscle endurance in chronic
obstructive pulmonary disease. Thorax 57: 132–136, 2002.
157. Ramirez-Sarmiento A, Orozco-Levi M, Guell R, Barreiro E, Her-
nandez N, Mota S, Sangenis M, Broquetas JM, Casan P, Gea J.
Inspiratory muscle training in patients with chronic obstructive pulmo-
nary disease: structural adaptation and physiologic outcomes. Am J
Respir Crit Care Med 166: 1491–1497, 2002.
158. Ramírez-Sarmiento A, Pascual S, Martinez-Llorens JM, Gea J,
Orozco-Levi M. Inspiratory muscle strength predicts mortality in pa-
tients with chronic obstructive pulmonary disease (Abstract). Eur Respir
J 36, Suppl: 611s, 2010.
159. Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK. A
syndrome of acute severe muscle necrosis in intensive care unit patients.
J Neuropathol Exp Neurol 52: 387–398, 1993.
160. Rehn TA, Munkvik M, Lunde PK, Sjaastad I, Sejersted OM. Intrinsic
skeletal muscle alterations in chronic heart failure patients: a disease-
specific myopathy or a result of deconditioning? Heart Fail Rev 17:
421–436, 2012.
161. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle
weakness induced by tumor necrosis factor-alpha: involvement of muscle
myofilaments. Am J Respir Crit Care Med 166: 479–484, 2002.
162. Reynolds TH 4th, Bodine SC, Lawrence JC Jr. Control of Ser2448
phosphorylation in the mammalian target of rapamycin by insulin and
skeletal muscle load. J Biol Chem 277: 17657–17662, 2002.
163. Ribera F, N’Guessan B, Zoll J, Fortin D, Serrurier B, Mettauer B,
Bigard X, Ventura-Clapier R, Lampert E. Mitochondrial electron
transport chain function is enhanced in inspiratory muscles of patients
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
167: 873–879, 2003.
164. Richardson RS, Leek BT, Gavin TP, Haseler LJ, Mudaliar SR,
Henry R, Mathieu-Costello O, Wagner PD. Reduced mechanical
efficiency in COPD but normal peak V˙ O2 with small muscle mass
exercise. Am J Respir Crit Care Med 169: 89–96, 2004.
165. Rochester DF, Braun NMT, Arora NS. Respiratory muscle strength in
chronic obstructive pulmonary disease. Am Rev Respir Dis 119: 151–154,
1979.
166. Rochester DF, Braun NM. Determinants of maximal inspiratory pres-
sure in chronic obstructive pulmonary disease. Am Rev Respir Dis 132:
42–47, 1985.
167. Rodriguez DA, Kalko S, Puig-Vilanova E, Perez-Olabarría M, Fal-
ciani F, Gea J, Cascante M, Barreiro E, Roca J. Muscle and blood
redox status after exercise training in severe COPD patients. Free Radic
Biol Med 52: 88–94, 2012.
168. Rodriguez DA, Alcarraz-Vizán G, Díaz-Moralli S, Reed M, Gómez
FP, Falciani F, Günther U, Roca J, Cascante M. Plasma metabolic
profile in COPD patients: effects of exercise and endurance training.
Metabolomics 8: 508–516, 2012.
169. Roig M, Eng JJ, MacIntyre DL, Road JD, Reid WD. Deficits in
muscle strength, mass, quality, and mobility in people with chronic
obstructive pulmonary disease. J Cardiopulm Rehabil Prev 31: 120–124,
2011.
170. Saey D, Ribeiro F. Resistance training preserves skeletal muscle func-
tion in patients with COPD who are hospitalised with an acute exacer-
bation. J Physiother 57: 194, 2011.
171. Sala E, Roca J, Marrades RM, Alonso J, Gonzalez de Suso JM,
Moreno A, Barbera` JA, Nadal J, de Jover L, Rodríguez-Roisín R,
Wagner PD. Effect of endurance training on skeletal muscle bioener-
getic in chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 159: 1726–1734, 1999.
172. Sanchez J, Brunet A, Medrano G, Debesse B, Derenne JP. Metabolic
enzymatic activities in the intercostal and serratus muscles and in the
latissimus dorsi of middle-aged normal men and patients with moderate
obstructive pulmonary disease. Eur Respir J 1: 376–383, 1988.
173. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A,
Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription
factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause
skeletal muscle atrophy. Cell 117: 399–412, 2004.
174. Satta A, Migliori GB, Spanevello A, Neri M, Bottinelli R, Canepari
M, Pellegrino MA, Reggiani C. Fibre types in skeletal muscles of
chronic obstructive pulmonary disease patients related to respiratory
function and exercise tolerance. Eur Respir J 10: 2853–2860, 1997.
175. Sauleda J, García-Palmer F, Wiesner RJ, Tarraga S, Harting I,
Tomás P, Gómez C, Saus C, Palou A, Agustí AG. Cytochrome oxidase
activity and mitochondrial gene expression in skeletal muscle of patients
with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
157: 1413–1417, 1998.
176. Scalvini S, Volterrani M, Vitacca M, Clark AL, Solfrini R, Panzali
AM, Ferrari R, Levi GF. Plasma hormone levels and haemodynamics
in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis
51: 380–386, 1996.
177. Schols AM, Soeters PB, Mostert R, Saris WH, Wouters EF. Energy
balance in chronic obstructive pulmonary disease. Am Rev Respir Dis
143: 1248–1252, 1991.
178. Schols AMWJ, Soeters PB, Dingemans MC, Mostert R, Frantzen PJ,
Wouters EFM. Prevalence and characteristics of nutritional depletion in
patients with stable COPD eligible for pulmonary rehabilitation. Am J
Respir Crit Care Med 147: 1151–1156, 1993.
179. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD,
Jackson A, Gosker HR, Schols AM, Moxham J, Polkey MI, Wouters
EF. The prevalence of quadriceps weakness in COPD and the relation-
ship with disease severity. Eur Respir J 36: 81–88, 2010.
Review
1233Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
180. Shiota S, Okada T, Naitoh H, Ochi R, Fukuchi Y. Hypoxia and
hypercapnia affect contractile and histological properties of rat dia-
phragm and hind limb muscles. Pathophysiology 11: 23–30, 2004.
181. Simard C, Maltais F, Leblanc P, Simard PM, Jobin J. Mitochondrial
and capillarity changes in vastus lateralis muscle of COPD patients:
electron microscopy study. Med Sci Sports Exerc 28: S95, 1996.
182. Similowsky Th, Yan S, Gaithier AP, Macklem PT. Contractile prop-
erties of the human diaphragm during chronic hyperinflation. N Engl J
Med 325: 917–923, 1991.
183. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in
COPD: a result of “overspill” of inflammatory mediators from the lungs?
Review of the evidence. Thorax 65: 930–936, 2010.
184. Singel DJ, Stamler JS. Blood traffic control. Nature 430: 297, 2004.
185. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G,
Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute
exacerbation in hospitalised patients with COPD and its relationship with
CXCL8 and IGF-I. Thorax 58: 752–756, 2003.
186. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO,
Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt path-
way prevents expression of muscle atrophy-induced ubiquitin ligases by
inhibiting FOXO transcription factors. Mol Cell 14: 395–403, 2004.
187. Subramanian HH, Holstege G. Midbrain and medullary control of
postinspiratory activity of the crural and costal diaphragm in vivo. J
Neurophysiol 105: 2852–2862, 2011.
188. Sun Z, Liu L, Liu N, Liu Y. Muscular response and adaptation to
diabetes mellitus. Front Biosci 13: 4765–4794, 2008.
189. Sundar IK, Yao H, Rahman I. Oxidative stress and chromatin remod-
eling in chronic obstructive pulmonary disease and smoking-related
diseases. Antioxid Redox Signal 2012 Nov 6. [Epub ahead of print].
190. Supinski G. Free radical-induced respiratory muscle dysfunction. Mol
Cell Biochem 179: 99–110, 1998.
191. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ,
Moore AJ, Moxham J, Polkey MI. Quadriceps strength predicts mor-
tality in patients with moderate to severe chronic obstructive pulmonary
disease. Thorax 62: 115–120, 2007.
192. Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki
H, Kato S, Tomoike H. The relationship between chronic hypoxemia
and activation of the tumor necrosis factor-alpha system in patients with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:
1179–1184, 2000.
193. Testelmans D, Crul T, Maes K, Agten A, Crombach M, Decramer M,
Gayan-Ramirez G. Atrophy and hypertrophy signalling in the dia-
phragm of patients with COPD. Eur Respir J 35: 549–56, 2010.
194. Troosters T, Probst VS, Crul T, Pitta F, Gayan-Ramirez G, Decramer
M, Gosselink R. Resistance training prevents deterioration in quadriceps
muscle function during acute exacerbations of chronic obstructive pul-
monary disease. Am J Respir Crit Care Med 181: 1072–1077, 2010.
195. Turan N, Kalko S, Stincone A, Clarke K, Sabah A, Howlett K,
Curnow SJ, Rodriguez DA, Cascante M, O’Neill L, Egginton S, Roca
J, Falciani F. A systems biology approach identifies molecular networks
defining skeletal muscle abnormalities in chronic obstructive pulmonary
disease. PLoS Comput Biol 7: e1002129, 2011.
196. Van den Borst B, Slot IG, Hellwig VA, Vosse BA, Kelders MC,
Barreiro E, Schols AM, Gosker HR. Loss of quadriceps muscle
oxidative phenotype and decreased endurance in patients with mild-to-
moderate COPD. J Appl Physiol (Published ahead of print July 19, 2012).
doi:10.1152/ japplphysiol.00508.2012.
197. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of
FoxO shuttling: mechanisms of FoxO translocation and transcriptional
regulation. Biochem J 380: 297–309, 2004.
198. Van Helvoort HA, Heijdra YF, Thijs HM, Viña J, Wanten GJ,
Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted
patients with COPD. Med Sci Sports Exerc 38: 1543–1552, 2006.
199. Van’t Hul A, Harlaar J, Gosselink R, Hollander P, Postmus P,
Kwakkel G. Quadriceps muscle endurance in patients with chronic
obstructive pulmonary disease. Muscle Nerve 29: 267–274, 2004.
200. Vermeeren MA, Schols AM, Wouters EF. Effects of an acute exacer-
bation on nutritional and metabolic profile of patients with COPD. Eur
Respir J 10: 2264–2269, 1997.
201. Vermeeren MAP, Creutzberg EC, Schols AM, Postma DS, Pieters
WR, Roldaan AC, Wouters EF; Study Group COSMIC. Prevalence
of nutritional depletion in a large out-patient population of patients with
COPD. Respir Med 100: 1349–1355, 2006.
202. Vestbo J, Prescott E, Almadal T, Dahl M, Nodestgaard BG, Ander-
sen T, Sørensen TI, Lange P. Body mass, fat-free body mass, and
prognosis in patients with chronic obstructive pulmonary disease from a
random population sample: findings from the Copenhagen City Heart
Study. Am J Respir Crit Care Med 173: 79–83, 2006.
203. Vilaró J, Ramirez-Sarmiento A, Martínez-Llorens JM, Mendoza T,
Alvarez M, Sánchez-Cayado N, Vega A, Gimeno E, Coronell C, Gea
J, Roca J, Orozco-Levi M. Global muscle dysfunction as a risk factor of
readmission to hospital due to COPD exacerbations. Respir Med 104:
1896–1902, 2010.
204. Vogiatzis I, Habazettl H, Aliverti A, Athanasopoulos D, Louvaris Z,
LoMauro A, Wagner H, Roussos C, Wagner PD, Zakynthinos S.
Effect of helium breathing on intercostal and quadriceps muscle blood
flow during exercise in COPD patients. Am J Physiol Regul Integr Comp
Physiol 300: R1549–R1559, 2011.
205. Waclawik AJ, Sufit RL, Beinlich BR, Schutta HS. Acute myopathy
with selective degeneration of myosin filaments following status asth-
maticus treated with methylprednisolone and vecuronium. Neuromuscul
Disord 2: 19–26, 1992.
206. Whittom F, Jobin J, Simard PM, LeBlanc P, Simard C, Bernard S,
Belleau R, Maltais F. Histochemical and morphological characteristics
of the vastus lateralis muscle in COPD patients. Med Sci Sports Exerc 30:
1467–1474, 1998.
207. Wijnhoven JH, Janssen AJ, van Kuppevelt TH, Rodenburg RJ,
Dekhuijzen PN. Metabolic capacity of the diaphragm in patients with
COPD. Respir Med 100: 1064–1071, 2006.
208. Wilson SH, Cooke NT, Edwards RH, Spiro SG. Predicted normal
values for maximal respiratory pressures in Caucasian adults and chil-
dren. Thorax 39: 535–538, 1984.
209. Wilson DO, Rogers RM, Hoffman RM. Nutrition and chronic lung
disease. Am Rev Respir Dis 132: 1347–1365, 1985.
210. Wüst RC, Morse CI, de Haan A, Rittweger J, Jones DA, Degens H.
Skeletal muscle properties and fatigue resistance in relation to smoking
history. Eur J Appl Physiol 104: 103–110, 2008.
211. Yang L, Zhou M, Smith M, yang G, Peto R, Wang J, Boreham J, Hu
Y, Chen Z. Body mass index and chronic obstructive pulmonary disease-
related mortality: a nationally representative prospective study of
220,000 men in China. Int J Epidemiol 39: 1027–1036, 2010.
212. Yohannes AM, Ershler WB. Anemia in COPD: a systematic review of
the prevalence, quality of life, and mortality. Respir Care 56: 644–652,
2011.
213. Yoneda T, Yoshikawa M, Fu A, Tsukaguchi K, Okamoto Y, Tak-
enaka H. Plasma levels of amino acids and hypermetabolism in patients
with chronic obstructive pulmonary disease. Nutrition 17: 95–99, 2001.
214. Yun Z, Lin Q, Giaccia AJ. Adaptive myogenesis under hypoxia. Mol
Cell Biol 25: 3040–3055, 2005.
215. Zhang J, Liu Y, Shi J, Larson DF, Watson RR. Side-stream cigarette
smoke induces dose-response in systemic inflammatory cytokine produc-
tion and oxidative stress. Exp Biol Med 227: 823–829, 2002.
Review
1234 Mechanisms of Muscle Dysfunction in COPD • Gea J et al.
J Appl Physiol • doi:10.1152/japplphysiol.00981.2012 • www.jappl.org
